» LEARN MORE ABOUT COVID-19 VACCINES, TESTING, VISITOR & SAFETY REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

NRG-GU005

Trial

Clinical Trial Title

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer

Trial Status

Open to Enrollment

Start Date

November 16, 2017

Trial Type

Cancer - Adult Oncology

Specific Condition

Prostate cancer

Description

This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Stereotactic body radiation therapy may work better in treating patients with prostate cancer.

Eligibility Criteria

Eligibility Criteria

  • Previously untreated (no local therapy such as surgery, radiation cryotherapy, HIFU, etc.) localized adenocarcinoma of the prostate
  • Age ≥ 18
  • History and physical including a digital rectal exam 60 days prior to registration
  • ECOG Performance Status 0-1
  • MRI of pelvis within 90 days prior to registration
  • Bone scan as clinically indicated within 90 days prior to registration
  • Willingness and ability to complete the Expanded Prostate Cancer Index Composite questionnaire

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

IRB Number

Central IRB

Principal Investigator Name

Andrew Kee, MD

Contact Name

Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Contact E-Mail

oncologyresearch@lhs.org

Last Updated: Wednesday, January 27, 2021 12:56:52 PM